Similarly, our method could aid in classifying CDKN2A/B-homozygous loss negative samples when proven on a larger cohort, and since loss of CDKN2A/B in IDH mutant astrocytoma is the principal biomarker for poor prognosis, we propose DMS’ potential for its rapid identification of patients with poorer prognosis, hence amenable to undergo GTR. Here, IDH2 is linked to astrocytoma (excluding glioblastoma).